GENE ONLINE|News &
Opinion
Blog

2021-11-10| China

Zai Lab Buys Rights to Three Assets, Including Its First Neuroscience Drug

by Joy Lin
Share To
Until recently, Zai Lab had been content with cultivating their collection of oncology assets, along with a few drugs targeting infectious and autoimmune diseases. That's why their latest deal, struck Tuesday with Blueprint Medicines for rights to two cancer drugs, seemed to be business as usual.

However, on the same day, the Chinese company marked a sudden shift in strategy by in-licensing their first neuroscience asset from another company, Karuna Therapeutics. The licensing deal with Karuna gives Zai Lab rights to the former's KarXT for development and commercialization in mainland China, Hong Kong, Macau, and Taiwan.

In its second collaboration, Zai Lab bought rights to develop and sell two Blueprint Medicines' lung cancer drugs, BLU-945 and BLU701, in China, Hong Kong, Macau, and Taiwan.

GO Prime with only $1.49 now

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top